High Expression of PKCζ And CTNNBIP1 Is Associated With Poor Prognosis in Luminal B Breast Cancer.

IF 2.6 4区医学 Q2 GENETICS & HEREDITY

Cancer Genomics & Proteomics Pub Date : 2025-06-26 DOI:10.21873/cgp.20520

Yuka Nagashima, Kazunori Sasaki, Ryosuke Chiwaki, Hayato Ishii, Kana Nohata, Yuki Maemura, Takahiro Kasai, Ayaka Ozaki, Shoma Tamori, Shigeo Ohno, Kazunori Akimoto

{"title":"High Expression of PKCζ And CTNNBIP1 Is Associated With Poor Prognosis in Luminal B Breast Cancer.","authors":"Yuka Nagashima, Kazunori Sasaki, Ryosuke Chiwaki, Hayato Ishii, Kana Nohata, Yuki Maemura, Takahiro Kasai, Ayaka Ozaki, Shoma Tamori, Shigeo Ohno, Kazunori Akimoto","doi":"10.21873/cgp.20520","DOIUrl":null,"url":null,"abstract":"Background/aim: The relationship between protein kinase C zeta (PKCζ) expression and medical treatment resistance in breast cancer subtypes is unclear. Therefore, the present study aimed to analyze this relationship using disease-specific survival.Materials and methods: Open-source datasets with clinical and gene expression information (METABRIC, n=2509; and TCGA Pan-Cancer Atlas, n=1084) were downloaded and Kaplan-Meier survival and Cox proportional hazard analyses were performed.Results: High expression of PKCζ indicated a poor prognosis in patients with luminal B type treated with endocrine therapy and aromatase inhibitor as endocrine therapy. Furthermore, catenin beta interacting protein 1 (CTNNBIP1) was identified as a differentially expressed gene between the PKCζ high and PKCζ low luminal B breast cancer cohorts treated with endocrine therapy and aromatase inhibitors. PKCζ high CTNNBIP1 high luminal B breast cancer treated with endocrine therapy and aromatase inhibitor indicated a poor prognosis. These results suggest that PKCζ and CTNNBIP1 are involved in breast cancer progression and contribute to reduced susceptibility to endocrine therapy in the luminal B breast cancer subtype.Conclusion: PKCζ and CTNNBIP1 may serve as a prognostic biomarker for predicting the efficacy of endocrine therapy in the luminal B breast cancer.","PeriodicalId":9516,"journal":{"name":"Cancer Genomics & Proteomics","volume":"22 4","pages":"538-556"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genomics & Proteomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/cgp.20520","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The relationship between protein kinase C zeta (PKCζ) expression and medical treatment resistance in breast cancer subtypes is unclear. Therefore, the present study aimed to analyze this relationship using disease-specific survival.

Materials and methods: Open-source datasets with clinical and gene expression information (METABRIC, n=2509; and TCGA Pan-Cancer Atlas, n=1084) were downloaded and Kaplan-Meier survival and Cox proportional hazard analyses were performed.

Results: High expression of PKCζ indicated a poor prognosis in patients with luminal B type treated with endocrine therapy and aromatase inhibitor as endocrine therapy. Furthermore, catenin beta interacting protein 1 (CTNNBIP1) was identified as a differentially expressed gene between the PKCζ ^high and PKCζ ^low luminal B breast cancer cohorts treated with endocrine therapy and aromatase inhibitors. PKCζ ^high CTNNBIP1 ^high luminal B breast cancer treated with endocrine therapy and aromatase inhibitor indicated a poor prognosis. These results suggest that PKCζ and CTNNBIP1 are involved in breast cancer progression and contribute to reduced susceptibility to endocrine therapy in the luminal B breast cancer subtype.

Conclusion: PKCζ and CTNNBIP1 may serve as a prognostic biomarker for predicting the efficacy of endocrine therapy in the luminal B breast cancer.

查看原文本刊更多论文

PKCζ和CTNNBIP1高表达与B腔乳腺癌预后不良相关

背景/目的：蛋白激酶Cζ (PKCζ)表达与乳腺癌亚型药物耐药性的关系尚不清楚。因此，本研究旨在用疾病特异性生存率来分析这种关系。材料和方法：包含临床和基因表达信息的开源数据集(METABRIC, n=2509；下载TCGA泛癌症图谱（n=1084），并进行Kaplan-Meier生存和Cox比例风险分析。结果：PKCζ高表达提示内分泌治疗和芳香化酶抑制剂作为内分泌治疗的luminal B型患者预后较差。此外，连环蛋白β相互作用蛋白1 （CTNNBIP1）被确定为PKCζ高和PKCζ低的luminal B乳腺癌队列中接受内分泌治疗和芳香化酶抑制剂的差异表达基因。PKCζ高CTNNBIP1高luminal B乳腺癌经内分泌治疗和芳香酶抑制剂治疗预后较差。这些结果表明PKCζ和CTNNBIP1参与了乳腺癌的进展，并有助于降低腔B乳腺癌亚型对内分泌治疗的易感性。结论：PKCζ和CTNNBIP1可作为预测B腔乳腺癌内分泌治疗效果的预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Genomics & Proteomics ONCOLOGY-GENETICS & HEREDITY

CiteScore

5.00

自引率

8.00%

发文量

期刊介绍： Cancer Genomics & Proteomics (CGP) is an international peer-reviewed journal designed to publish rapidly high quality articles and reviews on the application of genomic and proteomic technology to basic, experimental and clinical cancer research. In this site you may find information concerning the editorial board, editorial policy, issue contents, subscriptions, submission of manuscripts and advertising. The first issue of CGP circulated in January 2004. Cancer Genomics & Proteomics is a journal of the International Institute of Anticancer Research. From January 2013 CGP is converted to an online-only open access journal. Cancer Genomics & Proteomics supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.